Associate Professor  Susan Hua

Associate Professor Susan Hua

Associate Professor

School of Biomedical Sciences and Pharmacy (Pharmacy and Experimental Pharmacology)

In the world of the inconceivably small but mighty

Dr Susan Hua, recipient of the 2015 HMRI Early Career Researcher of the Year Award, is proving that some of the greatest gifts to human health come in the tiniest of packages.

Like a creative motor mechanic custom-building the ideal courier car, Dr Susan Hua is tinkering with vehicle parts to get parcels from A to B – just on a microscopic scale. She’s designing digitally-precise transport modules for pharmaceutical substances, masterfully applying nanotechnology to the diagnosis, prevention and treatment of disease.

“Most conventional medicines, such as tablets, capsules and injections, are essentially high doses of free drugs that are distributed to all parts of the body,” the pharmaceutics enthusiast elaborates.

“This means they’re not very efficient and increase the risk of adverse effects.”

“There are also some really great novel compounds in the research and development pipeline that are unable to reach the site of disease when delivered on its own.”

“These compounds either suffer from stability issues and are easily degraded following administration, or have physicochemical properties that affect their pharmacokinetics (movement of drug within the body).”

Susan’s research interest is in the cutting-edge field of therapeutic targeting – by making existing and new medicines work better with fewer side effects and toxicity through the use of nanotechnology. Essentially she is interested in designing and manufacturing “vehicles or carriers” that she can load these medicines into, and then modifying the surface of the vehicles to act like a “GPS” to direct the cargo to the site of disease. This allows the development of more effective and safer medications and diagnostic agents.

“This technology is important to allow compounds to bypass biological barriers that would otherwise degrade or hinder their accumulation at the target site,” she asserts.

“This allows maximum targeting efficacy with lower doses and frequency of doses, as well as reduced side effects and toxicity.”

“It’s fast-tracked translation.”

THE JOURNEY TO NANOMEDICINE

Susan completed her Bachelor of Pharmacy degree with Honours at The University of Queensland, attaining a prestigious University Medal, before working as a clinical pharmacist.

In this role she was able to see first-hand how so many of her patients were experiencing devastating side effects from medicines that were actually helping to treat or manage their condition, such as patients with cancer or chronic pain.

“Drugs tend to cause side effects when it harms the healthy cells in the body,” she explains.

“Chemotherapy treatment can take a heavy toll on a patient’s body causing debilitating effects such as fatigue, nausea, vomiting, pain, hair loss, decreased blood cell counts, and organ damage.”

“Chronic pain affects the quality of life of so many people, with current treatment limited by sedation, confusion, gastrointestinal upsets, respiratory depression, and dependence.”

Susan believed that there had to be a way we could improve these therapies.

“That’s when I realised that if I wanted to help make a change, I needed to become involved in research.”

This spurred her to pursue a PhD in the field of neuroscience and nanotechnology at The University of Queensland, where she sought to cement a systematic, nuanced understanding of the peripheral mechanisms of inflammatory pain.

“Immune cells contain a lot of useful endogenous analgesics that don’t have the nasty central side effects, such as sedation, dependence and nausea,” she explains.

By understanding the neuroimmune interaction between immune cells and the peripheral nervous system, she was able to use nanotechnology as a tool to mimic this activity exogenously.

“It was about understanding the intricate networks occurring in peripheral inflammatory conditions, and taking advantage of what the body already has to further suppress the pain and inflammation,” she states.

Prior to joining the University of Newcastle, Susan took on a postdoctoral position at the ANZAC Research Institute in Sydney to strengthen her research skills in biochemistry and cellular signalling. This time concentrating on the heart, she looked to gage the therapeutic consequences of oxidative stress on “good cholesterol” or high-density lipoproteins (HDLs) in cardioprotection.

PASSION FOR PHARMACY

Susan joined the University of Newcastle in mid-2010 as a teaching and research academic within the School of Biomedical Sciences and Pharmacy. She teaches intensively into the Masters and Bachelor of Pharmacy Programs in the fields of pharmacotherapeutics and pharmacy practice.

Passionate about the pharmacy profession, Susan enjoys using innovative teaching methods to reinforce key material in a clinically applied approach.

“When students understand why and how we use specific medicines to treat different conditions, they start to appreciate the advantages and disadvantages of current treatments from a pharmaceutical, pharmacotherapeutic and pharmacy practice perspective,” she says.

“Hopefully, this inspires them to become clinical leaders in the pharmacy profession or to improve disease outcomes by pursuing a research career.”

Starting from scratch

Susan has become a leader in the field of therapeutic targeting and translational nanopharmaceutics. Since joining the University of Newcastle, she has independently established the first translational nanopharmaceutics laboratory and research program in the Hunter region.

“There was no pharmaceutics laboratory or nanomedicine-based research program when I arrived, therefore I spent a lot of time establishing a new research program and laboratory from the ground up,” Susan affirms.

The general research focus of her laboratory is on therapeutic targeting utilising novel drug delivery platforms in biomedical applications.

“I am particularly interested in using nanotechnology to study novel mechanistic pathways, as well as to develop more efficient therapeutic delivery systems.”

Her research expertise covers the areas of advanced pharmaceutical formulation and characterisation, in vitro cellular studies and preclinical in vivo animal studies. This expertise provides a solid foundation to formulate and evaluate new drug delivery systems and to apply them to pathological disease states, in order to assess potential clinical applicability and identify novel therapeutic targets.

TRANSLATIONAL RESEARCH

Susan has already procured a number of competitive grants and patents, as well as established a productive publication track record. In 2015, she was awarded the HMRI Early Career Researcher of the Year Award, highlighting her significant and valued contribution to the research community.

The majority of her projects are translational and hence are currently under IP commercial in confidence stages. These projects have all applied the use of nanotechnology across a number of research disciplines. She has built strong collaborations with other major research groups locally at the Hunter Medical Research Institute and John Hunter Hospital, and around the world.

Susan is now balancing onsite pharmaceutical investigations with a multitude of fruitful collaborations.

“A number of my key projects are focused on developing novel treatments for pain and inflammation, an area in which I have established important animal models of acute and chronic pain at the University of Newcastle.”

Susan has also teamed up with Laureate Professor Nick Talley and Professor Marjorie Walker to launch the Priority Research Centre for Digestive Health and Neurogastroenterology.

“I’ve been able to work with these two amazing clinician scientists to develop new treatments for gastrointestinal diseases by targeting inflammatory cells in the gut,” she enthuses.

“The results have been exciting and have the potential to revolutionise the way we treat these patients”.

“I’m also working with Professor Roger Smith and Dr Jonathan Paul from the Mothers and Babies Research Centre, to develop a novel targeting system that will deliver contraction-blocking or contraction-inducing drugs to the uterus for preterm labour or postpartum haemorrhage.”

“Having a translational team is important in this field of research.”

This collaboration draws upon Susan’s specialised expertise in manufacturing the targeted liposomes, and couples her skills with Jonathan and Roger’s research expertise in reproductive medicine to apply the novel treatment platform to both human and animal models.

“A new grant from the National Health and Medical Research Council will help us fast-track this novel technology into primate studies,” she attests.

Big prospects for small engineering

The future is wide open for nanomedicine, and Susan is acutely aware of its promises.

“Putting free drugs into the body is not our best way forward,” she advocates.

“The goal of my research is to improve the way we treat patients through designing medicines and diagnostics that are better at specifically targeting the site of disease – in this way we are able to increase their effectiveness and significantly reduce the risk of side effects and toxicity.”

“These targeted therapeutic systems essentially act like a magic bullet.”

Related links

Susan Hua

In the world of the inconceivably small but mighty

Dr Susan Hua's research focus is on therapeutic targeting utilising novel drug delivery platforms in biomedical applications.

Read more

Career Summary

Biography

Associate Professor Susan Hua (BPharm, Hons, PhD, MPS) is an academic pharmacist and has been a full-time teaching and research (T&R) academic in the School of Biomedical Sciences and Pharmacy since 2010. She is a registered pharmacist in Australia and has several years’ experience across various fields of pharmacy, including hospital, community and research. A/Prof Hua has a Bachelor of Pharmacy degree and a PhD from the University of Queensland in the field of neuroscience and nanotechnology. Since her appointment at the University of Newcastle, A/Prof Hua has independently established the first translational nanopharmaceutics laboratory and research program in the Hunter region focused on therapeutic targeting using pharmaceutical technology and nanotechnology. Her background as a clinical pharmacist has given her a thorough clinical understanding of therapeutics and disease states, and has allowed her to identify promising research avenues in therapeutics and drug delivery. A/Prof Hua is the Head of the Therapeutic Targeting and Translational Nanopharmaceutics Research Program at the University of Newcastle, and Director of the Translational Pharmaceutics & Medical Technologies Theme for the Precision Medicine Research Program at the Hunter Medical Research Institute (HMRI). 

Research Expertise

The general research focus of A/Prof Hua's laboratory is on therapeutic targeting utilising novel drug delivery platforms in biomedical applications. She is particularly interested in using nanotechnology to study novel mechanistic pathways as well as to develop more efficient therapeutic delivery systems that are able to overcome biological barriers. Her key focus areas include (but are not limited to) gastrointestinal drug delivery, dermal and transdermal drug delivery, and parenteral drug delivery in clinical areas such as gastrointestinal diseases, musculoskeletal pathologies, infectious diseases, and reproductive pathologies. A/Prof Hua's research expertise covers the areas of advanced pharmaceutical formulation, in vitro cellular studies, and preclinical in vivo animal studies. This expertise provides a solid foundation to formulate and evaluate new drug delivery systems and to apply them to pathological disease states, in order to assess potential clinical applicability and identify novel therapeutic targets. A/Prof Hua’s research program provides a platform for the translational development of targeted therapeutics that will ultimately provide a novel therapeutic strategy in clinical disease management and provides a translational component to the research currently conducted in the Hunter New England region. 

Research Achievements

A/Prof Hua has secured in excess of $4 million in competitive research grants and infrastructure funding from a number of different sources. Highlights include successful NHMRC funding, a GAPPS international grant, the Pharmacy Research Trust of NSW grant, and funding from the Rebecca L. Cooper Medical Research Foundation. A/Prof Hua has also generated novel IP where she designed, manufactured, characterised and optimised novel drug delivery platforms for targeting reproductive pathologies (APP1050584 and APP1113847, #2014271207), as well as developed new delivery models for drugs that target inflammatory cells in the gut (#2016904629). Despite IP and commercial-in-confidence restrictions on a number of her projects, A/Prof Hua has established a productive publication track record, having first and/or senior authorship positions on ~80% of her publications - which are predominantly in Q1 journals. A/Prof Hua's research has been cited >6370 times, her h-index is 29, and her i10-index is 41 (Google Scholar). Her field-weighted citation impact (FWCI) from the last 10 years is 7.06 (SciVal). She is an associate editor for Frontiers in Science, an active external reviewer for grants and publications (in the field of nanotechnology, pharmaceutics, pharmacology, medical technology, and inflammation), and a member of the University of Newcastle Academy of Reviewers - which is a select and esteemed group of highly experienced researchers that act as a reference group for the Research and Innovation Division. A/Prof Hua was awarded the 2017 NSW Premier's Prize for Early Career Researcher of the Year, 2016 NSW Young Tall Poppy Science Award, 2016 Newcastle Innovation's Excellence in Innovation Award, 2016 Faculty Award for Research Excellence, and 2015 Hunter Medical Research Institute (HMRI) Early Career Researcher of the Year Award. In addition, she was invited to deliver two prestigious international Henry Stewart Talks for the Drug Delivery lecture series (2020 & 2021), which gathered leading world experts in the field.

Teaching and Administration

Since her appointment in 2010, A/Prof Hua has taken on a significant teaching workload in the Discipline of Pharmacy at the University of Newcastle. She teaches into the areas of Pharmacotherapeutics and Pharmacy Practice in the Bachelor of Pharmacy (Honours) program and previously into the Masters of Pharmacy program (superseded). A/Prof Hua has independently designed and developed a number of pharmacy courses from scratch, incorporating a diversity of teaching methodologies and techniques that she has developed and adapted from her own experience in Pharmacy. Her goal as a teacher is to instil a passion for learning within her students while providing them with an educational environment that is encouraging and positive. A/Prof Hua was awarded the 2020 DVC(A) Educator Innovation and Impact Award for developing 'Innovative teaching methods for real-world clinical pharmacy education', and 2011 Faculty Award for Teaching and Learning Commendation. She is the Bachelor of Pharmacy Honours Program Coordinator, and Pharmacy Advisor on the Institutional Biosafety Committee (IBC). 

A/Prof Hua strongly believes in the importance of high quality teaching and positive motivation of pharmacy students and junior pharmacists to sustain the quality use of medicines in the community.  


Qualifications

  • Doctor of Philosophy, University of Queensland
  • Bachelor of Pharmacy, University of Queensland

Keywords

  • Active targeting
  • Acute and chronic pain
  • Biological barriers
  • Dermal and transdermal drug delivery
  • Gastrointestinal drug delivery
  • Inflammation
  • Lipid-based delivery systems
  • Nanodiagnostics
  • Nanomedicines
  • Nanotechnology
  • Parenteral drug delivery
  • Passive targeting
  • Pharmaceutics
  • Pharmacology
  • Pharmacy
  • Preclinical studies
  • Targeted drug delivery
  • Theranostic nanoparticles
  • Therapeutic targeting
  • Translational nanopharmaceutics

Fields of Research

Code Description Percentage
321402 Clinical pharmacology and therapeutics 50
321405 Pharmaceutical sciences 50

Professional Experience

UON Appointment

Title Organisation / Department
Associate Professor University of Newcastle
School of Biomedical Sciences and Pharmacy
Australia

Awards

Award

Year Award
2020 DVC(A) Educator Innovation and Impact Award
The University of Newcastle
2017 NSW Premier's Prize for Early Career Researcher of the Year
Office of the NSW Chief Scientist and Engineer
2016 Excellence in Innovation Award
Newcastle Innovation, The University of Newcastle
2016 Faculty Award for Research Excellence
The University of Newcastle - Faculty of Health and Medicine
2016 NSW Young Tall Poppy Science Award
AIPS (Australian Institute of Policy and Science)
2016 Brawn Fellowship
Faculty of Health, University of Newcastle
2015 HMRI Early Career Researcher of the Year
Hunter Medical Research Institute
2011 Teaching and Learning Commendation
The University of Newcastle

Patents

Number Title Patent Family Registered Approved
AU2014271207, US20160113872, EP2999461A1 TARGETED DELIVERY OF DRUGS TO THE MYOMETRIUM
TARGETED DELIVERY OF DRUGS TO THE MYOMETRIUM
TARGETED DELIVERY OF DRUGS TO THE MYOMETRIUM 22/5/2014 2014
2016904629 FORMULATIONS FOR THE TREATMENT OF MUCOSAL INFLAMMATORY DISORDERS
FORMULATIONS FOR THE TREATMENT OF MUCOSAL INFLAMMATORY DISORDERS
FORMULATIONS FOR THE TREATMENT OF MUCOSAL INFLAMMATORY DISORDERS 14/11/2016 2016

Grant Reviews

Year Grant Amount
2023 DevelopMed - Marie Skłodowska-Curie COFUND Action (Ireland) Reviewer & Rapporteur
International - Competitive - 3IFA, International - Competitive - 3IFA
$0
2023 NHMRC GRP Member (Ideas Grant Scheme)
C1100 - Aust Competitive - NHMRC - 1100, C1100 - Aust Competitive - NHMRC - 1100
$0
2022 DevelopMed - Marie Skłodowska-Curie COFUND Action (Ireland) Reviewer & Rapporteur
International - Competitive - 3IFA, International - Competitive - 3IFA
$0
2022 NHMRC GRP Member (Ideas Grant Scheme)
C1100 - Aust Competitive - NHMRC - 1100, C1100 - Aust Competitive - NHMRC - 1100
$0
2022 MRFF Early to Mid-Career Researcher Clinical Medicine and Science Grant Assessment Committee (GAC)
C1300 - Aust Competitive - Medical Research Future Fund - 1300, C1300 - Aust Competitive - Medical Research Future Fund - 1300
$0
2022 Medical Research Council (MRC UK) Clinical Academic Research Partnerships Grant Reviewer
International - Competitive - 3IFA, International - Competitive - 3IFA
$0
2022 UON Academy of Reviewers
Internal - INTE, Internal - INTE
$0
2021 UON Academy of Reviewers
Internal - INTE, Internal - INTE
$0
2021 Medical Research Council (MRC UK) Developmental Pathway Funding Scheme (DPFS) Reviewer
International - Competitive - 3IFA, International - Competitive - 3IFA
$0
2021 Health Research Council of New Zealand (HRC) Grant Reviewer
International - Competitive - 3IFA, International - Competitive - 3IFA
$0
2020 UON Academy of Reviewers
Internal - INTE, Internal - INTE
$0
2020 NHMRC GRP Member (Investigator Grant Scheme)
C1100 - Aust Competitive - NHMRC - 1100, C1100 - Aust Competitive - NHMRC - 1100
$0
2020 NHMRC GRP Member (Ideas Grant Scheme)
C1100 - Aust Competitive - NHMRC - 1100, C1100 - Aust Competitive - NHMRC - 1100
$0
2020 National Institutes of Health (NIH US) Grant Reviewer
International - Competitive - 3IFA, International - Competitive - 3IFA
$0
2019 Geneva University Hospitals and Faculty of Medicine Research Foundation Reviewer
International - Competitive - 3IFA, International - Competitive - 3IFA
$0
2019 NHMRC GRP Member (Investigator Grant Scheme)
C1100 - Aust Competitive - NHMRC - 1100, C1100 - Aust Competitive - NHMRC - 1100
$0
2018 Swiss National Science Foundation Research Grant Reviewer
International - Competitive - 3IFA, International - Competitive - 3IFA
$0
2018 NHMRC GRP Member (Project Grant Scheme)
Aust Competitive - Commonwealth - 1CS, Aust Competitive - Commonwealth - 1CS
$0
2017 Medical Research Council (MRC UK) Developmental Pathway Funding Scheme (DPFS) Reviewer
International - Competitive - 3IFA, International - Competitive - 3IFA
$0
2017 Medical Research Council (MRC UK) Project Grant Reviewer
International - Competitive - 3IFA, International - Competitive - 3IFA
$0
2017 Novo Nordisk Foundation Interdisciplinary Synergy Programme Reviewer
International - Competitive - 3IFA, International - Competitive - 3IFA
$0
2016 National Science Centre (NCN Poland) Grant Reviewer
International - Competitive - 3IFA, International - Competitive - 3IFA
$0

Teaching

Code Course Role Duration
PHAR6211 Pharmacy Practice 4
Faculty of Health, University of Newcastle
Course coordinator, course development, lecturer and tutor 6/5/2010 - 31/12/2014
PHAR2101 Dermatology and Topical Formulations
Faculty of Health, University of Newcastle
Course coordinator, course development, lecturer and tutor 1/1/2014 - 31/12/2020
PHAR2204 Clinical Pharmacotherapy 1
University of Newcastle
Course coordinator, course development, lecturer and tutor 1/1/2021 - 1/1/2025
PHAR4103B Pharmacy Research Project B (Sem 2)
The University of Newcastle
Bachelor of Pharmacy Graded Honours Program Coordinator 24/11/2021 - 24/12/2025
PHAR4104B Pharmacy Projects B (Sem 2)
The University of Newcastle
Bachelor of Pharmacy Ungraded Honours Program Coordinator 24/11/2021 - 24/12/2025
PHAR2102 Cardiovascular and Renal Health
Faculty of Health, University of Newcastle
Course coordinator, course development, lecturer and tutor 1/1/2014 - 31/12/2020
PHAR4104A Pharmacy Projects A (Sem 1)
The University of Newcastle
Bachelor of Pharmacy Ungraded Honours Program Coordinator 24/11/2021 - 24/12/2025
PHAR4101 Cancer, Critical Care & Palliative Care
The University of Newcastle
Course coordinator, course development, lecturer and tutor 1/1/2021 - 1/1/2025
PHAR6133 Pharmacotherapeutics 1
Faculty of Health, University of Newcastle
Course coordinator, course development, lecturer and tutor 6/5/2010 - 31/12/2013
PHAR4103A Pharmacy Research Project A (Sem 1)
The University of Newcastle
Bachelor of Pharmacy Graded Honours Program Coordinator 24/11/2021 - 24/12/2025
Edit

Publications

For publications that are currently unpublished or in-press, details are shown in italics.

Highlighted Publications

Year Citation Altmetrics Link
2013 Hua S, Cabot PJ, 'Targeted Nanoparticles that Mimic Immune Cells in Pain Control Inducing Analgesic and Anti-inflammatory Actions: A Potential Novel Treatment of Acute and Chronic Pain Conditions', PAIN PHYSICIAN, 16 E199-E216 (2013) [C1]
Citations Scopus - 59Web of Science - 49
2015 Sercombe L, Veerati T, Moheimani F, Wu SY, Sood AK, Hua S, 'Advances and challenges of liposome assisted drug delivery', Frontiers in Pharmacology, 6 (2015) [C1]

The application of liposomes to assist drug delivery has already had a major impact on many biomedical areas. They have been shown to be beneficial for stabilizing therapeutic com... [more]

The application of liposomes to assist drug delivery has already had a major impact on many biomedical areas. They have been shown to be beneficial for stabilizing therapeutic compounds, overcoming obstacles to cellular and tissue uptake, and improving biodistribution of compounds to target sites in vivo. This enables effective delivery of encapsulated compounds to target sites while minimizing systemic toxicity. Liposomes present as an attractive delivery system due to their flexible physicochemical and biophysical properties, which allow easy manipulation to address different delivery considerations. Despite considerable research in the last 50 years and the plethora of positive results in preclinical studies, the clinical translation of liposome assisted drug delivery platforms has progressed incrementally. In this review, we will discuss the advances in liposome assisted drug delivery, biological challenges that still remain, and current clinical and experimental use of liposomes for biomedical applications. The translational obstacles of liposomal technology will also be presented.

DOI 10.3389/fphar.2015.00286
Citations Scopus - 1664Web of Science - 1297
2015 Hua S, Marks E, Schneider JJ, Keely S, 'Advances in oral nano-delivery systems for colon targeted drug delivery in inflammatory bowel disease: selective targeting to diseased versus healthy tissue.', Nanomedicine, 11 1117-1132 (2015) [C1]
DOI 10.1016/j.nano.2015.02.018
Citations Scopus - 407Web of Science - 311
Co-authors Jennifer Schneider, Simon Keely
2018 Hua S, de Matos MBC, Metselaar JM, Storm G, 'Current Trends and Challenges in the Clinical Translation of Nanoparticulate Nanomedicines: Pathways for Translational Development and Commercialization', FRONTIERS IN PHARMACOLOGY, 9 (2018) [C1]
DOI 10.3389/fphar.2018.00790
Citations Scopus - 579Web of Science - 402
2019 Hua S, 'Synthesis and in vitro characterization of oxytocin receptor targeted PEGylated immunoliposomes for drug delivery to the uterus', Journal of Liposome Research, 29 357-367 (2019) [C1]

Targeted delivery of therapeutics to the uterus is an important goal in the treatment of obstetric complications, such as preterm labour, postpartum hemorrhage, and dysfunctional ... [more]

Targeted delivery of therapeutics to the uterus is an important goal in the treatment of obstetric complications, such as preterm labour, postpartum hemorrhage, and dysfunctional labour. Current treatment for these obstetric complications is challenging, as there are limited effective and safe therapeutic options available. We have developed a targeted drug delivery system for the uterus by conjugating anti-oxytocin receptor (OTR) antibodies to the surface of PEGylated liposomes (OTR-PEG-ILs). The functionality of the OTR-PEG-ILs has previously been evaluated on human and murine myometrial tissues as well as in vivo in a murine model of preterm labour. The aim of this study was to report the pharmaceutical synthesis and characterization of the OTR-PEG-ILs and investigate their specific cellular interaction with OTR-expressing myometrial cells in vitro. Immunoliposomes composed of 1,2-distearoyl-sn-glycero-2-phosphocholine (DSPC) and cholesterol were prepared using an optimized method for the coupling of low concentrations of antibody to liposomes. The liposomes were characterized for particle size, antibody conjugation, drug encapsulation, liposome stability, specificity of binding, cellular internalization, mechanistic pathway of cellular uptake, and cellular toxicity. Cellular association studies demonstrated specific binding of OTR-PEG-ILs to OTRs and significant cellular uptake following binding. Evaluation of the mechanistic pathway of cellular uptake indicated that they undergo internalization through both clathrin- and caveolin-mediated mechanisms. Furthermore, cellular toxicity studies have shown no significant effect of OTR-PEG-ILs or the endocytotic inhibitors on cell viability. This study further supports oxytocin receptors as a novel pharmaceutical target for drug delivery to the uterus.

DOI 10.1080/08982104.2018.1556293
Citations Scopus - 15Web of Science - 12
2019 Hua S, Vaughan B, 'In vitro comparison of liposomal drug delivery systems targeting the oxytocin receptor: a potential novel treatment for obstetric complications', INTERNATIONAL JOURNAL OF NANOMEDICINE, 14 2191-2206 (2019) [C1]
DOI 10.2147/IJN.S198116
Citations Scopus - 17Web of Science - 13

Book (2 outputs)

Year Citation Altmetrics Link
2019 Hua S, Wu S, Advances and Challenges in Nanomedicine, Frontiers, Switzerland, 153 (2019)
DOI 10.3389/978-2-88945-745-8
2015 Hua SH, Cabot PJ, PAIN - Novel Targets and New Technologies, Frontiers in Pharmacology, Switzerland, 95 (2015) [A4]
DOI 10.3389/978-2-88919-394-3

Chapter (1 outputs)

Year Citation Altmetrics Link
2017 Hua S, 'Bridging the gap between the bench and the clinic: Inflammat ory bowel disease', Nanomedicine for Inflammatory Diseases 145-170 (2017)

Inflammatory bowel disease (IBD) is a localized, chronic inflammatory condition that affects the gastrointestinal (GI) wall. Currently, there is no cure for IBD, with therapeutic ... [more]

Inflammatory bowel disease (IBD) is a localized, chronic inflammatory condition that affects the gastrointestinal (GI) wall. Currently, there is no cure for IBD, with therapeutic strategies aimed toward attaining and maintaining remission from inflammatory episodes. While conventional medications can temporarily induce and maintain remission, 70% of IBD patients will require at least one surgical intervention in their lifetime (Byrne et al. 2007; Talley et al. 2011). Due to the chronic nature of IBD and the impact the disease has on patient compliance to medications, oral formulations are the preferred route of administration (Saini et al. 2009). Conventional oral formulations have limited use in IBD, as they are generally designed to achieve systemic delivery of therapeutics, which results in adverse effects and toxicity following distribution of drug around the body (Hua et al. 2015). These formulations can be adversely affected during active IBD or following 146intestinal resection, and have limited efficacy and specificity for diseased GI tissue versus healthy GI tissue (Malayandi et al. 2014). In addition, despite coverage of the GI surface (including diseased tissue), there is no guarantee that the drug is effectively taken up into the tissue and cells at the site of inflammation (Hua 2014). Oral formulations achieving a localized effect are preferred in rational drug delivery design for IBD. This ensures that drug will be delivered to the site of action within the GI tract, but will not be absorbed or will be poorly absorbed to avoid unwanted side effects (Talaei et al. 2013; Hua et al. 2015).

DOI 10.1201/978131515235
Citations Scopus - 2

Journal article (49 outputs)

Year Citation Altmetrics Link
2024 Duchatel RJ, Jackson ER, Parackal SG, Kiltschewskij D, Findlay IJ, Mannan A, et al., 'PI3K/mTOR is a therapeutically targetable genetic dependency in diffuse intrinsic pontine glioma.', J Clin Invest, 134 (2024) [C1]
DOI 10.1172/JCI170329
Citations Scopus - 2
Co-authors Murray Cairns, David Skerrett-Byrne, Muhammad Jamaluddin, Heather Murray, Lizzie Manning, Matt Dun, Christopher Dayas, Brett Nixon, Ryan Duchatel
2023 Hua S, Lye EC, 'Impact of gastric and bowel surgery on gastrointestinal drug delivery', DRUG DELIVERY AND TRANSLATIONAL RESEARCH, 13 37-53 (2023) [C1]
DOI 10.1007/s13346-022-01179-6
Citations Scopus - 2Web of Science - 1
2023 Lim AW, Talley NJ, Walker MM, Storm G, Hua S, 'Current status and advances in esophageal drug delivery technology: influence of physiological, pathophysiological and pharmaceutical factors.', Drug delivery, 30 2219423 (2023) [C1]
DOI 10.1080/10717544.2023.2219423
Citations Scopus - 4
Co-authors Marjorie Walker, Nicholas Talley
2023 Yang K, Hua S, Wei W, Yang C, Zhu X, Li SC, 'Economic burden of advanced lung cancer patients treated by gefitinib alone and combined with chemotherapy in two regions of China.', J Med Econ, 26 1424-1431 (2023) [C1]
DOI 10.1080/13696998.2023.2272536
Co-authors Shuchuen Li
2023 Brown Y, Hua S, Tanwar PS, 'Extracellular matrix in high-grade serous ovarian cancer: Advances in understanding of carcinogenesis and cancer biology.', Matrix Biol, 118 16-46 (2023) [C1]
DOI 10.1016/j.matbio.2023.02.004
Citations Scopus - 10Web of Science - 1
Co-authors Pradeep Tanwar
2022 Dong PTX, Pham VTT, Nguyen LT, Le AV, Nguyen TT, Vu HD, et al., 'Impact of pharmacist-initiated educational interventions on improving medication reconciliation practice in geriatric inpatients during hospital admission in Vietnam', Journal of Clinical Pharmacy and Therapeutics, 47 2107-2114 (2022) [C1]

What is known and objective: Unintentional medication discrepancies (UMDs) are common in geriatric patients during care transitions, resulting in frequent undesirable consequences... [more]

What is known and objective: Unintentional medication discrepancies (UMDs) are common in geriatric patients during care transitions, resulting in frequent undesirable consequences. Medication reconciliation could be a useful practice to prevent or ameliorate UMD. However, this practice in Vietnamese hospitals has not been well established or standardized. This study aims to determine the effect of pharmacist-initiated educational interventions on improving medication reconciliation practice. Methods: This prospective 6-month pre-and post-study was conducted in two internal medicine wards in a Vietnamese 800-bed public hospital. Pharmacists provided training and short-term support to physicians on medication reconciliation. Primary outcome measures were the proportions of patients with at least one UMD at admission. Secondary outcome measures were the proportions of patients with preventable adverse drug events (pADEs) score =0.1 due to these UMDs. Odds ratio and 95% confidence intervals were assessed based on a multivariate logistic regression model. Results and discussion: One hundred fifty-two patients were recruited in the pre-intervention phase, and 146 in the post-intervention phase. Following the intervention, the proportion of geriatric patients with =1 UMD at admission significantly decreased from 55.3 to 25.3¿% (ORadj 0.255, 95% CI: 0.151¿0.431). Similarly, the proportion of patients with a pADE =0.1 at admission reduced from 44.1 to 11.6% [ORadj 0.188, 95% CI: 0.105¿0.340] post-intervention. What is new and conclusion: Our pharmacist-initiated educational interventions have demonstrated the ability to produce substantial improvement in medication reconciliation practice, reducing UMDs and potential harm. Our approach may provide an alternate option to implement medication reconciliation for jurisdictions with limited healthcare resources.

DOI 10.1111/jcpt.13758
Co-authors Shuchuen Li
2022 Dong PTX, Trinh HT, Nguyen DH, Nguyen ST, Pham VTT, Ngo HB, et al., 'Implementing clinical pharmacy activities in hospital setting in Vietnam: current status from a national survey', BMC HEALTH SERVICES RESEARCH, 22 (2022) [C1]
DOI 10.1186/s12913-022-08242-5
Citations Scopus - 5Web of Science - 2
Co-authors Shuchuen Li
2022 Bains J, Carver S, Hua S, 'Pathophysiological and Pharmaceutical Considerations for Enhancing the Control of Sarcoptes scabiei in Wombats Through Improved Transdermal Drug Delivery', Frontiers in Veterinary Science, 9 (2022) [C1]

Sarcoptic scabiei is an invasive parasitic mite that negatively impacts wombats, causing sarcoptic mange disease, characterized by alopecia, intense pruritus, hyperkeratosis, and ... [more]

Sarcoptic scabiei is an invasive parasitic mite that negatively impacts wombats, causing sarcoptic mange disease, characterized by alopecia, intense pruritus, hyperkeratosis, and eventual mortality. Evidence suggests that wombats may be unable to recovery from infection without the assistance of treatments. Transdermal drug delivery is considered the most ideal route of administration for in situ treatment in free-ranging wombats, as it is non-invasive and avoids the need to capture affected individuals. Although there are effective antiparasitic drugs available, an essential challenge is adequate administration of drugs and sufficient drug retention and absorption when delivered. This review will describe the implications of sarcoptic mange on the physiology of wombats as well as discuss the most widely used antiparasitic drugs to treat S. scabiei (ivermectin, moxidectin, and fluralaner). The prospects for improved absorption of these drugs will be addressed in the context of pathophysiological and pharmaceutical considerations influencing transdermal drug delivery in wombats with sarcoptic mange.

DOI 10.3389/fvets.2022.944578
Citations Scopus - 5
2022 Dong PTX, Pham VTT, Nguyen TT, Nguyen HTL, Hua S, Li SC, 'Unintentional Medication Discrepancies at Admission Among Elderly Inpatients with Chronic Medical Conditions in Vietnam: A Single-Centre Observational Study', Drugs - Real World Outcomes, 9 141-151 (2022) [C1]

Background: Elderly patients are at high risk of unintentional medication discrepancies during transition¿of care as they are more likely to have multiple comorbidities and chroni... [more]

Background: Elderly patients are at high risk of unintentional medication discrepancies during transition¿of care as they are more likely to have multiple comorbidities and chronic diseases that require multiple medications. Objective: The aim of the study was to assess the frequency of unintentional medication discrepancies and identify the associated risk factors and potential clinical impact of them in elderly inpatients during hospital admission. Patients and Methods: A prospective observational study was conducted from July to December 2018 in an 800-bed geriatric hospital in Hanoi, North Vietnam. Patients over 60 years of age, admitted to one of selected internal medicine wards, taking at least one chronic medication before admission, and staying at least 48 h were eligible for enrollment. Medication discrepancies of chronic medications before and after admission of each participant were identified by a pharmacist using a step-by-step protocol for the medication reconciliation process. The identified discrepancies were then classified as intentional or unintentional by an assessment group comprising a pharmacist and a physician. A logistic regression model was used to identify risk factors of medication discrepancies. Results: Among 192 enrolled patients, 328 medication discrepancies were identified, with 87 (26.5%) identified as unintentional. Nearly a third of enrolled patients (32.3%) had at least one unintentional medication discrepancy. The most common unintentional medication discrepancy was omission of drugs (75.9% of 87 medication discrepancies). The logistic regression analysis revealed a positive association between the number of discrepancies at admission and the type of treatment wards. Conclusions: Medication discrepancies are common at admission among Vietnamese elderly inpatients. This study highlights the importance of obtaining a comprehensive medication history at hospital admission and supports implementing a medication reconciliation program to reduce the negative impact of medication discrepancy, especially for the elderly population.

DOI 10.1007/s40801-021-00274-3
Citations Scopus - 4Web of Science - 3
Co-authors Shuchuen Li
2022 Dong PTX, Pham VTT, Dinh CT, Van Le A, Tran HTH, Nguyen HTL, et al., 'Implementation and Evaluation of Clinical Pharmacy Services on Improving Quality of Prescribing in Geriatric Inpatients in Vietnam: An Example in a Low Resources Setting', Clinical Interventions in Aging, 17 1127-1138 (2022) [C1]

Purpose: Geriatric inpatients generally have a high risk of drug-related problems (DRP) in prescribing following hospital admission, which are likely to cause negative clinical co... [more]

Purpose: Geriatric inpatients generally have a high risk of drug-related problems (DRP) in prescribing following hospital admission, which are likely to cause negative clinical consequences. This is particularly evident in developing countries such as Vietnam. Therefore, clinical pharmacy service (CPS) aims to identify and resolve these DRPs to improve the quality use of medicines in the older population following hospital admission. Patients and Methods: The study was conducted as a prospective, single-center study implemented at a general public hospital in Hanoi. Patients aged =60 years with at least three chronic diseases admitted to the Internal Medicine Department between August 2020 and December 2020 were eligible to be enrolled. A well-trained clinical pharmacist provided a structured CPS to identify any DRP in prescribing for each patient in the study. Clinical pharmacist interventions were then proposed to the attending physicians and documented in the DRP reporting system. Results: A total of 255 DRP were identified in 185 patients during the study period. The most frequent types of DRP were underuse (21.2%), dose too high (12.2%), and contraindication (11.8%). There was a very high rate of approval and uptake by the physicians regarding the interventions proposed by the clinical pharmacist (82.4% fully accepted and 12.5% partially accepted). Of the interventions, 73.4% were clinically relevant (pADE score =0.1). In general, 9 out of 10 physicians agreed that CPS has significant benefits for both patients and physicians. Conclusion: Improving clinical pharmacy services can potentially have a positive impact on the quality of prescribing in elderly inpatients. These services should officially be implemented to optimize the quality use of medicines in this population group in Vietnam.

DOI 10.2147/CIA.S368871
Citations Scopus - 2Web of Science - 1
Co-authors Shuchuen Li
2020 Hua S, 'Advances in Oral Drug Delivery for Regional Targeting in the Gastrointestinal Tract - Influence of Physiological, Pathophysiological and Pharmaceutical Factors', Frontiers in Pharmacology, 11 (2020) [C1]
DOI 10.3389/fphar.2020.00524
Citations Scopus - 220Web of Science - 113
2020 Arms L, Robson AL, Woldu A, Martin A, Palmer W, Flynn J, Hua S, 'Considerations for using optical clearing techniques for 3D imaging of nanoparticle biodistribution', International Journal of Pharmaceutics, 588 (2020) [C1]
DOI 10.1016/j.ijpharm.2020.119739
Citations Scopus - 3Web of Science - 1
Co-authors Jamie Flynn
2019 Hua S, 'Synthesis and in vitro characterization of oxytocin receptor targeted PEGylated immunoliposomes for drug delivery to the uterus', Journal of Liposome Research, 29 357-367 (2019) [C1]

Targeted delivery of therapeutics to the uterus is an important goal in the treatment of obstetric complications, such as preterm labour, postpartum hemorrhage, and dysfunctional ... [more]

Targeted delivery of therapeutics to the uterus is an important goal in the treatment of obstetric complications, such as preterm labour, postpartum hemorrhage, and dysfunctional labour. Current treatment for these obstetric complications is challenging, as there are limited effective and safe therapeutic options available. We have developed a targeted drug delivery system for the uterus by conjugating anti-oxytocin receptor (OTR) antibodies to the surface of PEGylated liposomes (OTR-PEG-ILs). The functionality of the OTR-PEG-ILs has previously been evaluated on human and murine myometrial tissues as well as in vivo in a murine model of preterm labour. The aim of this study was to report the pharmaceutical synthesis and characterization of the OTR-PEG-ILs and investigate their specific cellular interaction with OTR-expressing myometrial cells in vitro. Immunoliposomes composed of 1,2-distearoyl-sn-glycero-2-phosphocholine (DSPC) and cholesterol were prepared using an optimized method for the coupling of low concentrations of antibody to liposomes. The liposomes were characterized for particle size, antibody conjugation, drug encapsulation, liposome stability, specificity of binding, cellular internalization, mechanistic pathway of cellular uptake, and cellular toxicity. Cellular association studies demonstrated specific binding of OTR-PEG-ILs to OTRs and significant cellular uptake following binding. Evaluation of the mechanistic pathway of cellular uptake indicated that they undergo internalization through both clathrin- and caveolin-mediated mechanisms. Furthermore, cellular toxicity studies have shown no significant effect of OTR-PEG-ILs or the endocytotic inhibitors on cell viability. This study further supports oxytocin receptors as a novel pharmaceutical target for drug delivery to the uterus.

DOI 10.1080/08982104.2018.1556293
Citations Scopus - 15Web of Science - 12
2019 Brown Y, Hua S, Tanwar PS, 'Extracellular matrix-mediated regulation of cancer stem cells and chemoresistance', International Journal of Biochemistry and Cell Biology, 109 90-104 (2019) [C1]

The identity of cancer stem cells (CSCs) remains an enigma, with the question outstanding of whether CSCs are fixed entities or plastic cell states in response to microenvironment... [more]

The identity of cancer stem cells (CSCs) remains an enigma, with the question outstanding of whether CSCs are fixed entities or plastic cell states in response to microenvironmental cues. Recent evidence highlights the power of the tumor microenvironment to dictate CSC functionality and spatiotemporal regulation that gives rise to tumor heterogeneity. This microenvironmental regulation of CSCs parallels that of normal tissues, whereby resident stem cells reside within specialized microenvironments or ¿niches¿, which provide the cellular and molecular signals that wire every aspect of stem cell behavior and fate. The extracellular matrix (ECM), along with its sequestered growth factors, is a fundamental component of the stem cell niche. Pathological ECM remodeling is an established hallmark of cancer, with the ECM a key mediator of metastasis and drug resistance. In this review, we discuss the controversial identity of CSCs and new understanding of the impact of tumor microenvironment on CSC function and phenotype. We outline parallels between development, wound repair and cancer to discuss how changes in ECM dynamics influence stem cell function during normal physiological processes and pathological states, as well as the transition between the two in the form of precancerous lesions. We then explore examples illustrating the molecular circuits partnering cancer cells with stromal cells and how this communication involving ECM imparts a CSC phenotype and promotes chemoresistance. Understanding the mechanisms underlying CSC functionality and chemoresistance, along with mathematical modeling approaches and advancing technologies for targeting the undruggable proteome, should open opportunities for cancer breakthroughs in the future.

DOI 10.1016/j.biocel.2019.02.002
Citations Scopus - 58Web of Science - 45
Co-authors Pradeep Tanwar
2019 Nguyen TS, Nguyen TLH, Pham TTV, Hua S, Ngo QC, Li SC, 'Impact of pharmaceutical care in the improvement of medication adherence and quality of life for COPD patients in Vietnam', Respiratory Medicine, 153 31-37 (2019) [C1]

Background: Medication adherence is an important factor in the management of chronic obstructive pulmonary disease (COPD). However, the rate of non-adherence to medications is hig... [more]

Background: Medication adherence is an important factor in the management of chronic obstructive pulmonary disease (COPD). However, the rate of non-adherence to medications is high in COPD and is associated with worsened clinical outcomes and health-related quality of life for patients. Objectives: Our study aimed to evaluate the impact of a pharmaceutical care program led by pharmacists in the improvement of medication adherence and quality of life for COPD patients in Vietnam. Methods: A pre- and post-intervention study was conducted over 12 months. Pharmacists provided brief counselling which focused on the role of COPD medications and the importance of adherence. Morisky Medication Adherence Scale was used to evaluate patients¿ adherence. Quality of life was assessed using the EQ-5D-5L questionnaire and clinical outcomes were evaluated by symptom scores. These outcomes were reassessed at baseline (T0), after 3 months (T1), 6 months (T2) and 12 months (T3). Results: Study participants consisted of 211 COPD patients (mean age: 66.6 ± 8.2 years). The percentage of patients with good adherence significantly increased from 37.4% to 53.2% (p < 0.001) after the program. Mean medication adherence scores improved from 6.7 (T0) to 7.4 (T2) and 7.4 (T3) (p < 0.001). EQ-5D-5L index values also increased from 0.47 (T0) to 0.59 (T3) (p < 0.001). There was no significant change in symptom scores across the duration of the study. Conclusions: Medication adherence and quality of life of COPD patients improved considerably after implementation of a pharmaceutical care program, thus supporting a vital role for pharmacists alongside physicians in the management of COPD.

DOI 10.1016/j.rmed.2019.05.006
Citations Scopus - 13Web of Science - 9
Co-authors Shuchuen Li
2019 Hua S, 'Advances in nanoparticulate drug delivery approaches for sublingual and buccal administration', Frontiers in Pharmacology, 10 (2019) [C1]
DOI 10.3389/fphar.2019.01328
Citations Scopus - 109Web of Science - 52
2019 Hua S, 'Physiological and Pharmaceutical Considerations for Rectal Drug Formulations', FRONTIERS IN PHARMACOLOGY, 10 (2019) [C1]
DOI 10.3389/fphar.2019.01196
Citations Scopus - 105Web of Science - 48
2019 Hua S, Vaughan B, 'In vitro comparison of liposomal drug delivery systems targeting the oxytocin receptor: a potential novel treatment for obstetric complications', INTERNATIONAL JOURNAL OF NANOMEDICINE, 14 2191-2206 (2019) [C1]
DOI 10.2147/IJN.S198116
Citations Scopus - 17Web of Science - 13
2018 Hua S, de Matos MBC, Metselaar JM, Storm G, 'Current Trends and Challenges in the Clinical Translation of Nanoparticulate Nanomedicines: Pathways for Translational Development and Commercialization', FRONTIERS IN PHARMACOLOGY, 9 (2018) [C1]
DOI 10.3389/fphar.2018.00790
Citations Scopus - 579Web of Science - 402
2018 Nguyen TS, Nguyen TLH, Van Pham TT, Hua S, Ngo QC, Li SC, 'Pharmacists training to improve inhaler technique of patients with COPD in vietnam', International Journal of COPD, 13 1863-1872 (2018) [C1]

Background: Incorrect use of inhalers is very common and subsequently leads to poor control of COPD. Among health care providers, pharmacists are in the best position to educate p... [more]

Background: Incorrect use of inhalers is very common and subsequently leads to poor control of COPD. Among health care providers, pharmacists are in the best position to educate patients about the correct use of inhaler devices. Objective: The objective of this study was to evaluate the impact of pharmacist-led training on the improvement of inhaler technique for COPD patients in Vietnam. Patients and methods: For this pre-and post-intervention study, standardized checklists of correct use of metered-dose inhalers (MDIs) and dry powder inhalers (DPIs) were used to evaluate the inhaler technique. A scoring system (maximum score =8) was applied before and after training to guarantee assessment uniformity among pharmacists. Three methods including ¿face-to-face training¿, ¿teach-back¿ and ¿technique reminder label¿ were used. After the baseline evaluation (T0), the inhaler technique was reassessed after 1 month (T1), 3 months (T2), 6 months (T3) and 12 months (T4). Results: A total of 211 COPD patients participated in the study. Before the training, a high rate of errors was recorded. After the training, the percentage of patients using MDIs and DPIs perfectly increased significantly (p,0.05). The mean technique score for MDIs and DPIs improved from 6.0 (T0) to 7.5 (T3) and 6.9 (T4) and 6.7 (T0) to 7.6 (T3) and 7.2 (T4), respectively (p,0.05). The average training time was 6 minutes (T0) and 3 minutes (T3), respectively. Conclusion: Pharmacist-led comprehensive inhaler technique intervention program using an unbiased and simple scoring system can significantly improve the inhaler techniques in COPD patients. Our results indicated a 3-month period as the optimal time period between training and retraining for maintaining the correct inhaler technique. The training would be highly feasible and suitable for implementing in the clinical setting. Our model of pharmacist-led training should be considered as an effective solution for managing COPD patients and better utilization of health care human resources, especially in a developing country like Vietnam.

DOI 10.2147/COPD.S163826
Citations Scopus - 28Web of Science - 20
Co-authors Shuchuen Li
2018 Robson AL, Dastoor PC, Flynn J, Palmer W, Martin A, Smith DW, et al., 'Advantages and limitations of current imaging techniques for characterizing liposome morphology', Frontiers in Pharmacology, 9 (2018) [C1]
DOI 10.3389/fphar.2018.00080
Citations Scopus - 110Web of Science - 76
Co-authors Jamie Flynn, Douglas Smith, Paul Dastoor
2018 Nguyen TS, Nguyen TLH, Pham TTV, Cao TBT, Nguyen VK, Hua S, Li SC, 'Effectiveness of a short training program for community pharmacists to improve knowledge and practice of asthma counselling A simulated patient study', Respiratory Medicine, 144 50-60 (2018) [C1]

Objective: Community pharmacists can make significant contributions and be an indispensable member in the asthma therapy chain. The present study aimed to investigate the current ... [more]

Objective: Community pharmacists can make significant contributions and be an indispensable member in the asthma therapy chain. The present study aimed to investigate the current knowledge level of Vietnamese community pharmacists in asthma counselling and the impact of a short training program on asthma knowledge and practice. Method: 300 community pharmacists participated in the study. A knowledge questionnaire about asthma medications and a standardized inhaler checklist were designed to evaluate their knowledge before and after a 4-h training program. Six to eight weeks later, 10 simulated patients were sent to the community pharmacies to evaluate the pharmacists¿ knowledge and practice. Results: The training program significantly improved the asthma knowledge score of pharmacists from 5.3 to 17.2 out of a maximum score of 20 (p < 0.001). After the training, the percentage of pharmacists performing correctly inhaler devices increased significantly (0% vs.~50%, p < 0.001). In the simulated patient study, pharmacists who attended the training demonstrated better asthma knowledge with higher scores (5.4 vs 1.7 out of a maximum score of 7.0, p < 0.001), as well as much better inhaler technique scores (6.1 vs 4.3, out of a maximum score of 8, p < 0.001). These pharmacists achieved higher scores in all aspects encompassing distinguishing controllers and relievers, counselling correctly about adherence, and common side effects. Conclusion: Our results revealed significant knowledge deficiency about asthma among Vietnamese community pharmacists. However, a short training program was effective in upskilling the pharmacists to effectively counsel asthmatic patients about the management of their condition and medications.

DOI 10.1016/j.rmed.2018.10.003
Citations Scopus - 7Web of Science - 7
Co-authors Shuchuen Li
2018 Arms L, Smith DW, Flynn J, Palmer W, Martin A, Woldu A, Hua S, 'Advantages and limitations of current techniques for analyzing the biodistribution of nanoparticles', Frontiers in Pharmacology, 9 1-17 (2018) [C1]
DOI 10.3389/fphar.2018.00802
Citations Scopus - 88Web of Science - 47
Co-authors Douglas Smith, Jamie Flynn
2018 Hua S, Wu SY, 'Advances and Challenges in Nanomedicine', FRONTIERS IN PHARMACOLOGY, 9 (2018)
DOI 10.3389/fphar.2018.01397
Citations Scopus - 26Web of Science - 15
2017 Hua S, Dias TH, Pepperall D-G, Yang Y, 'Topical Loperamide-Encapsulated Liposomal Gel Increases the Severity of Inflammation and Accelerates Disease Progression in the Adjuvant-Induced Model of Experimental Rheumatoid Arthritis', FRONTIERS IN PHARMACOLOGY, 8 (2017) [C1]
DOI 10.3389/fphar.2017.00503
Citations Scopus - 16Web of Science - 11
2017 Paul JW, Hua S, Ilicic M, Tolosa JM, Butler T, Robertson S, Smith R, 'Drug delivery to the human and mouse uterus using immunoliposomes targeted to the oxytocin receptor', AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 216 (2017) [C1]
DOI 10.1016/j.ajog.2016.08.027
Citations Scopus - 70Web of Science - 48
Co-authors Marina Paul, Jonathan Paul, Roger Smith
2016 Hua S, Dias TH, 'Hypoxia-Inducible Factor (HIF) as a Target for Novel Therapies in Rheumatoid Arthritis', FRONTIERS IN PHARMACOLOGY, 7 (2016) [C1]
DOI 10.3389/fphar.2016.00184
Citations Scopus - 81Web of Science - 61
2016 Hua S, 'Neuroimmune Interaction in the Regulation of Peripheral Opioid-Mediated Analgesia in Inflammation', FRONTIERS IN IMMUNOLOGY, 7 (2016) [C1]
DOI 10.3389/fimmu.2016.00293
Citations Scopus - 25Web of Science - 23
2016 Stone T, Hua S, Turale S, 'Evaluation of an international and interprofessional collaboration forum', Nurse Education Today, 46 10-16 (2016) [C1]

Background International and interprofessional collaborations are increasingly becoming a core requirement for health professionals in our globalized world. Aim The aim of this st... [more]

Background International and interprofessional collaborations are increasingly becoming a core requirement for health professionals in our globalized world. Aim The aim of this study was to evaluate the effectiveness of the Asia Pacific Alliance of Health Leaders (APAHL) Forum to enhance the development of international perspectives and leadership among students and faculty in the discipline of health. Methods This pilot study used a student-designed questionnaire to evaluate the views of students and faculty members about the effectiveness of APAHL in meeting its goals. Quantitative data from the scaled items on the questionnaire were analyzed by aggregating the data. Qualitative data were analyzed using a qualitative descriptive approach. Results Study participants comprised of 22 health science (nursing and laboratory science) students and 15 faculty members. Both faculty and students agreed that APAHL was effective in leadership development of students, as well as in advancing internationalization, interprofessional collaboration, and cultural awareness among students. A clear theme among the students was acknowledgement of the importance of communication, in particular being proficient in English. Difficulties in communication were an issue for both students and faculty members. Conclusion This pilot study has shown the benefits of a student-focused international forum in developing cross-cultural awareness, and will provide the groundwork for evaluating the effectiveness of cross-cultural and interprofessional leadership forums aimed particularly at students of health.

DOI 10.1016/j.nedt.2016.06.023
Citations Scopus - 7Web of Science - 4
2016 Hua S, Cook D, Walker MM, Talley NJ, 'Pharmacological treatment of eosinophilic gastrointestinal disorders', Expert Review of Clinical Pharmacology, 9 1195-1209 (2016) [C1]

Introduction: Eosinophilic gastrointestinal disorders (EGIDs) are increasingly prevalent chronic inflammatory diseases characterized by eosinophilic infiltration of the gastrointe... [more]

Introduction: Eosinophilic gastrointestinal disorders (EGIDs) are increasingly prevalent chronic inflammatory diseases characterized by eosinophilic infiltration of the gastrointestinal (GI) tract, in the absence of other known causes of eosinophilia. Areas covered: Clinical management of EGIDs is challenging, as there are currently limited therapeutic options available. The most common EGID is eosinophilic esophagitis (EoE), and rarer forms are eosinophilic gastritis, eosinophilic gastroenteritis, and eosinophilic colitis. Clinical presentation depends on the affected GI site. Recently duodenal eosinophilia has been recognized to commonly be present in patients with functional dyspepsia. This review will provide an overview of the pathogenesis and therapeutic management of EGIDs, with particular focus on the pharmacological strategies for these conditions. Expert commentary: Despite the considerable progress made in understanding the pathogenesis of EGIDs, there is still an urgent need for the development of specific and effective therapeutic approaches. Therapeutic management protocols are required that are based on rigorous clinical investigation in large prospective controlled trials to better understand the risks, benefits and limitations of each therapy. More well-defined and consistent end-points are also required to assess treatment outcomes, as there has been variability between patient reported outcomes, clinical outcomes, and histological outcomes in the studies to date.

DOI 10.1080/17512433.2016.1190268
Citations Scopus - 10Web of Science - 6
Co-authors Nicholas Talley, Marjorie Walker
2016 Mateer SW, Cardona J, Marks E, Goggin BJ, Hua S, Keely S, 'Ex Vivo Intestinal Sacs to Assess Mucosal Permeability in Models of Gastrointestinal Disease.', J Vis Exp, e53250 (2016) [C1]
DOI 10.3791/53250
Citations Scopus - 43Web of Science - 27
Co-authors Simon Keely
2015 Sercombe L, Veerati T, Moheimani F, Wu SY, Sood AK, Hua S, 'Advances and challenges of liposome assisted drug delivery', Frontiers in Pharmacology, 6 (2015) [C1]

The application of liposomes to assist drug delivery has already had a major impact on many biomedical areas. They have been shown to be beneficial for stabilizing therapeutic com... [more]

The application of liposomes to assist drug delivery has already had a major impact on many biomedical areas. They have been shown to be beneficial for stabilizing therapeutic compounds, overcoming obstacles to cellular and tissue uptake, and improving biodistribution of compounds to target sites in vivo. This enables effective delivery of encapsulated compounds to target sites while minimizing systemic toxicity. Liposomes present as an attractive delivery system due to their flexible physicochemical and biophysical properties, which allow easy manipulation to address different delivery considerations. Despite considerable research in the last 50 years and the plethora of positive results in preclinical studies, the clinical translation of liposome assisted drug delivery platforms has progressed incrementally. In this review, we will discuss the advances in liposome assisted drug delivery, biological challenges that still remain, and current clinical and experimental use of liposomes for biomedical applications. The translational obstacles of liposomal technology will also be presented.

DOI 10.3389/fphar.2015.00286
Citations Scopus - 1664Web of Science - 1297
2015 Hua S, Marks E, Schneider JJ, Keely S, 'Advances in oral nano-delivery systems for colon targeted drug delivery in inflammatory bowel disease: selective targeting to diseased versus healthy tissue.', Nanomedicine, 11 1117-1132 (2015) [C1]
DOI 10.1016/j.nano.2015.02.018
Citations Scopus - 407Web of Science - 311
Co-authors Jennifer Schneider, Simon Keely
2015 Hua S, 'Lipid-based nano-delivery systems for skin delivery of drugs and bioactives.', Frontiers in pharmacology, 6 219 (2015) [C1]
DOI 10.3389/fphar.2015.00219
Citations Scopus - 199Web of Science - 150
2014 Jobling P, O'Hara K, Hua S, 'Female reproductive tract pain: Targets, challenges, and outcomes', Frontiers in Pharmacology, 5 FEB (2014) [C1]

Pain from the female reproductive tract (FRT) is a significant clinical problem for which there are few effective therapies. The complex neuroanatomy of pelvic organs not only mak... [more]

Pain from the female reproductive tract (FRT) is a significant clinical problem for which there are few effective therapies. The complex neuroanatomy of pelvic organs not only makes diagnosis of pelvic pain disorders difficult but represents a challenge to development of targeted therapies. A number of potential therapeutic targets have been identified on sensory neurons supplying the FRT but our knowledge on the basic neurophysiology of these neurons is limited compared with other viscera. Until this is addressed we can only guess if the new experimental therapies proposed for somatic, gastrointestinal, or bladder pain will translate to the FRT. Once suitable therapeutic targets become clear, the next challenge is drug delivery. The FRT represents a promising system for topical drug delivery that could be tailored to act locally or systemically depending on formulation. Development of these therapies and their delivery systems will need to be done in concert with more robust in vivo and in vitro models of FRT pain. © 2014 Jobling, O'Hara and Hua.

DOI 10.3389/fphar.2014.00017
Citations Scopus - 10Web of Science - 15
Co-authors Phillip Jobling
2014 Hua S, 'Comparison of in vitro dialysis release methods of loperamide-encapsulated liposomal gel for topical drug delivery', International Journal of Nanomedicine, 9 735-744 (2014) [C1]

Background: The purpose of this study was to determine the most appropriate dialysis equilibrium method to assess liposomal gel formulations containing hydrophobic drugs, to give ... [more]

Background: The purpose of this study was to determine the most appropriate dialysis equilibrium method to assess liposomal gel formulations containing hydrophobic drugs, to give the most accurate indication of drug release. Methods: Loperamide hydrochloride-encapsulated liposomes, composed of L-a-phosphatidylcholine and cholesterol (molar ratio of 2:1), were prepared according to the method of dried lipid film hydration. The liposomes were incorporated into a carbopol gel (0.5%, weight/weight). The release of the drug from the nanoparticles was assessed using a number of variations of the dialysis technique, taking into account solubility parameters and formulation. Method 1 (below saturation point) and Method 2 (above saturation point) used a dilution method to evaluate how drug concentration and solubility affects the in vitro drug-release profile of loperamide hydrochloride, while Methods 3 (below saturation point) and 4 (above saturation point) evaluated how drug concentration and the gel base affect the release profile. Results: In Method 1, the liposomes showed a rapid release of just over 60% in the first 3 hours and then a slower, sustained release to just over 70% at 24 hours. Method 2 showed a gradual, sustained release profile with the liposomes with 55% release at 24 hours. In Method 3, the liposomes showed a rapid burst release of 98% at 2 hours. In Method 4, the liposomal gel had a rapid release of 60% within 3 hours and then a more gradual, sustained release with 86% release at 24 hours. The free drug suspension in Methods 2 and 4 showed a limited release across the dialysis membrane, in comparison to Methods 1 and 3, which showed a complete release in a timely manner. Conclusion: This study has demonstrated that the actual method used for equilibrium dialysis plays a significant role in determining the true characteristics of a topical nanoformulation, with Method 3 providing the most accurate indication of the release of a hydrophobic drug from a topical liposomal formulation. © 2014 Hua.

DOI 10.2147/IJN.S55805
Citations Scopus - 73Web of Science - 58
2014 Iwaszkiewicz KS, Hua S, 'Development of an effective topical liposomal formulation for localized analgesia and antiinflammatory actions in the Complete Freund s Adjuvant rodent model of acute inflammatory pain', Pain Physician, 17 E719-E735 (2014) [C1]

Background: Peripheral opioid receptor targeting has been well established as a novel target in clinical pain management for acute and chronic peripheral inflammatory pain. The ph... [more]

Background: Peripheral opioid receptor targeting has been well established as a novel target in clinical pain management for acute and chronic peripheral inflammatory pain. The physiochemical properties of the peripheral mu-opioid receptor agonist, loperamide HCl, limit the use of the free drug as an analgesic or anti-inflammatory agent, particularly for dermal delivery across intact skin.

Citations Scopus - 29Web of Science - 21
2014 Hua S, Cabot PJ, 'PAIN - Novel targets and new technologies', Frontiers in Pharmacology, 5 (2014) [C3]
DOI 10.3389/fphar.2014.00211
Citations Scopus - 3Web of Science - 2
2014 Hua S, 'Orally administered liposomal formulations for colon targeted drug delivery', Frontiers in Pharmacology, 5 JUN 1-4 (2014) [C2]
DOI 10.3389/fphar.2014.00138
Citations Scopus - 54Web of Science - 35
2013 Hua S, 'Targeting sites of inflammation: intercellular adhesion molecule-1 as a target for novel inflammatory therapies.', Front Pharmacol, 4 127 (2013) [C1]
DOI 10.3389/fphar.2013.00127
Citations Scopus - 93Web of Science - 69
2013 Hua S, Wu SY, 'The use of lipid-based nanocarriers for targeted pain therapies', Frontiers in Pharmacology, 4 NOV (2013) [C1]
DOI 10.3389/fphar.2013.00143
Citations Scopus - 173Web of Science - 112
2013 Iwaszkiewicz KS, Schneider JJ, Hua S, 'Targeting peripheral opioid receptors to promote analgesic and anti-inflammatory actions.', Front Pharmacol, 4 132 (2013) [C1]
DOI 10.3389/fphar.2013.00132
Citations Scopus - 80Web of Science - 71
Co-authors Jennifer Schneider
2013 Hua S, Cabot PJ, 'Targeted Nanoparticles that Mimic Immune Cells in Pain Control Inducing Analgesic and Anti-inflammatory Actions: A Potential Novel Treatment of Acute and Chronic Pain Conditions', PAIN PHYSICIAN, 16 E199-E216 (2013) [C1]
Citations Scopus - 59Web of Science - 49
2011 Witting PK, Song C, Hsu K, Hua S, Parry SN, Aran R, et al., 'The acute phase protein serum amyloid A induces endothelial dysfunction that is inhibited by high-density lipoprotein.', Free Radical Biology and Medicine, 51 1390-1398 (2011) [C1]
Citations Scopus - 33Web of Science - 30
2011 Hua S, Chang H-I, Davies N, Cabot PJ, 'Targeting of ICAM-1-directed immunoliposomes specifically to activated endothelial cells with low cellular uptake: use of an optimized procedure for the coupling of low concentrations of antibody to liposomes.', Journal of Liposome Research, 21 95-105 (2011) [C1]
DOI 10.3109/08982101003754401
Citations Scopus - 14Web of Science - 13
2010 Hua S, Cabot PJ, 'Mechanisms of peripheral immune-cell-mediated analgesia in inflammation: Clinical and therapeutic implications', Trends in Pharmacological Sciences, 31 427-433 (2010) [C1]
DOI 10.1016/j.tips.2010.05.008
Citations Scopus - 63Web of Science - 58
2009 Rayner BS, Hua S, Sabaretnam T, Witting PK, 'Nitric oxide stimulates myoglobin gene and protein expression in vascular smooth muscle.', Biochemical Journal, 423 169-177 (2009) [C1]
Citations Scopus - 25Web of Science - 24
2009 Hua S, Geczy CL, Freedman SB, Witting PK, 'A role for acute-phase serum amyloid A and high-density lipoprotein in oxidative stress, endothelial dysfunction and atherosclerosis.', Redox Report, 14 187-196 (2009) [C1]
Citations Scopus - 64Web of Science - 52
2006 Hua S, Hermanussen S, Tang L, Monteith GR, Cabot PJ, 'The neural cell adhesion molecule antibody blocks cold water swim stress-induced analgesia and cell adhesion between lymphocytes and cultured dorsal root ganglion neurons', Anesthesia and Analgesia, 103 1558-1564 (2006) [C1]
DOI 10.1213/01.ane.0000243410.61451.c1
Citations Scopus - 30Web of Science - 28
Show 46 more journal articles

Conference (1 outputs)

Year Citation Altmetrics Link
2023 Duchatel R, Jackson E, Parackal S, Sun C, Daniel P, Mannan A, et al., 'EXPLOITING THE GENETIC DEPENDENCY ON PI3K/ MTOR SIGNALING FOR THE TREATMENT OF H3-ALTERED DIFFUSE MIDLINE GLIOMA', NEURO-ONCOLOGY, CANADA, Vancouver (2023)
Co-authors David Skerrett-Byrne, Ryan Duchatel, Matt Dun, Muhammad Jamaluddin, Brett Nixon, Murray Cairns

Preprint (1 outputs)

Year Citation Altmetrics Link
2023 Duchatel R, Jackson E, Parackal S, Sun C, Daniel P, Mannan A, et al., 'PI3K/mTOR is a therapeutically targetable genetic dependency in diffuse intrinsic pontine glioma (2023)
DOI 10.1101/2023.04.17.537256
Co-authors Lizzie Manning, Heather Murray, Murray Cairns, David Skerrett-Byrne, Matt Dun, Muhammad Jamaluddin, Ryan Duchatel, Brett Nixon

Presentation (2 outputs)

Year Citation Altmetrics Link
2021 Hua S, 'Henry Stewart Talks (HS Talks) on 'Gastrointestinal Drug Delivery' . Biomedical & Life Sciences Collection - Drug Delivery Lecture Series (Editor: Prof Vladimir Torchilin, Northeastern University, USA)', (2021)
2020 Hua S, 'Henry Stewart Talks (HS Talks) on 'Drug Delivery to the Colon'. Biomedical & Life Sciences Collection - Drug Delivery Lecture Series (Editor: Prof Vladimir Torchilin, Northeastern University, USA)', (2020)
Edit

Grants and Funding

Summary

Number of grants 39
Total funding $4,670,486

Click on a grant title below to expand the full details for that specific grant.


20242 grants / $563,000

Small Animal In Vivo Imaging Facility with microCT imaging capabilities$450,000

Funding body: ARC (Australian Research Council)

Funding body ARC (Australian Research Council)
Project Team Associate Professor Susan Hua, Distinguished Emeritus Professor John Aitken, Professor Pradeep Tanwar, Doctor Behnam Akhavan, Associate Professor Nikki Verrills
Scheme Linkage Infrastructure Equipment & Facilities (LIEF)
Role Lead
Funding Start 2024
Funding Finish 2024
GNo G2300219
Type Of Funding Scheme excluded from IGS
Category EXCL
UON Y

Utilising a translational nanopharmaceutics approach to improving drug delivery in diffuse intrinsic pontine glioma$113,000

Funding body: Mark Hughes Foundation

Funding body Mark Hughes Foundation
Project Team Associate Professor Susan Hua, Miss Lauren Arms, Doctor Ryan Duchatel, Professor Matt Dun, Miss Evie Jackson
Scheme Innovation Grant
Role Lead
Funding Start 2024
Funding Finish 2025
GNo G2301481
Type Of Funding Scheme excluded from IGS
Category EXCL
UON Y

20232 grants / $15,452

Plasma-bioengineered hybrid hydrogels: Advanced nano-composite systems for drug delivery and precision cancer therapy $8,452

Funding body: Hunter Medical Research Institute - Precision Medicine Research Program

Funding body Hunter Medical Research Institute - Precision Medicine Research Program
Project Team

Dr Behnam Akhavan, A/Prof Susan Hua, Dr Gerard Kaiko

Scheme PMRP ECR/MCR Support Scheme
Role Investigator
Funding Start 2023
Funding Finish 2023
GNo
Type Of Funding Internal
Category INTE
UON N

Utilising a precision medicine approach to improving drug delivery in diffuse intrinsic pontine glioma$7,000

Funding body: Hunter Medical Research Institute - Precision Medicine Research Program

Funding body Hunter Medical Research Institute - Precision Medicine Research Program
Project Team

A/Prof Susan Hua, Prof Matt Dun, Dr Ryan Duchatel, Dr Evie Jackson, Lauren Arms

Scheme PMRP ECR/MCR Support Scheme
Role Lead
Funding Start 2023
Funding Finish 2024
GNo
Type Of Funding Internal
Category INTE
UON N

20222 grants / $652,386

2022 MRSP - Precision Medicine Research Program$524,736

Funding body: NSW Ministry of Health

Funding body NSW Ministry of Health
Project Team

Professor Murray Cairns, Associate Professor Nikki Verrills, Associate Professor Susan Hua, Doctor Heather Lee, Doctor Anoop Enjeti, Associate Professor Matt Dun

Scheme Medical Research Support Program (MRSP)
Role Investigator
Funding Start 2022
Funding Finish 2023
GNo
Type Of Funding External
Category EXTE
UON N

2022 Philanthropy - Precision Medicine Research Program$127,650

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team

Professor Murray Cairns, Associate Professor Nikki Verrills, Associate Professor Susan Hua, Doctor Heather Lee, Doctor Anoop Enjeti, Associate Professor Matt Dun

Scheme Research Grant
Role Investigator
Funding Start 2022
Funding Finish 2023
GNo
Type Of Funding C3300 – Aust Philanthropy
Category 3300
UON N

20211 grants / $68,836

Nano-micro fiber manufacturing$68,836

Funding body: The University of Newcastle

Funding body The University of Newcastle
Project Team

Ajay Singh Karakoti, Mark Baker, Jiabao Yi, A/Prof. Thomas Fiedler, Thomas Nann, Ajayan Vinu, Jangmee Lee, Susan Hua, Pradeep Tanwar, Lei Jin, Xu Dong Wang, Hubert Hondermarck, Shafiq Syed

Scheme Strategic Investment in Research Scheme
Role Investigator
Funding Start 2021
Funding Finish 2021
GNo
Type Of Funding Internal
Category INTE
UON N

20202 grants / $609,742

Development of Improved Treatments for Oesophageal Diseases$587,884

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Associate Professor Susan Hua, Ms Qian Xi Lim, Prof Gert Storm
Scheme Ideas Grants
Role Lead
Funding Start 2020
Funding Finish 2023
GNo G1900421
Type Of Funding C1100 - Aust Competitive - NHMRC
Category 1100
UON Y

Compresstome® VF-310-0Z Tissue Slicer$21,858

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team

Professor Pradeep Tanwar, Doctor Muhammad Fairuz Jamaluddin, Professor Xu Dong Zhang, Associate Professor Ajay Karakoti, Associate Professor Lei Jin, Associate Professor Susan Hua

Scheme Equipment Grant
Role Investigator
Funding Start 2020
Funding Finish 2020
GNo
Type Of Funding C1100 - Aust Competitive - NHMRC
Category 1100
UON N

20192 grants / $142,362

Research Equipment Grant$94,500

Funding body: University of Newcastle

Funding body University of Newcastle
Project Team

Susan Hua

Scheme Research Equipment Grant
Role Lead
Funding Start 2019
Funding Finish 2019
GNo
Type Of Funding Internal
Category INTE
UON N

Microinjection workstation to facilitate disease modelling in organoids$47,862

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Professor Pradeep Tanwar, Professor Xu Dong Zhang, Associate Professor Lei Jin, Professor Hubert Hondermarck, Associate Professor Susan Hua, Doctor Muhammad Fairuz Jamaluddin
Scheme Equipment Grant
Role Investigator
Funding Start 2019
Funding Finish 2019
GNo G1900304
Type Of Funding Scheme excluded from IGS
Category EXCL
UON Y

20181 grants / $3,960

A Targeted Drug Delivery System for the Uterus: MRI Characterisation of Nanoliposome Biodistribution$3,960

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team

Jonathan Paul, Susan Hua and Roger Smith

Scheme HMRI Imaging Centre Pilot Grant
Role Investigator
Funding Start 2018
Funding Finish 2018
GNo
Type Of Funding Internal
Category INTE
UON N

20176 grants / $1,001,016

Epithelial metabolism as a mediator of host-microbiome interactions in inflammatory bowel disease$857,419

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Professor Simon Keely, Professor Mark Morrison, Dr Paraic O Cuiv, Professor Martin Veysey, Associate Professor Susan Hua
Scheme Project Grant
Role Investigator
Funding Start 2017
Funding Finish 2019
GNo G1600412
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON Y

Evaluation of the effect of micro- and nanoparticulate dust exposure in the mining industry on human health and the development of an early detection system $50,000

Funding body: The University of Newcastle

Funding body The University of Newcastle
Project Team

Co-leads: Dr Susan Hua, A/Prof Kenneth Williams, A/Prof Thomas Fiedler, Dr Yolanda Surjan

Scheme Multi-disciplinary Innovation Pilot Grant
Role Lead
Funding Start 2017
Funding Finish 2018
GNo
Type Of Funding Internal
Category INTE
UON N

Investigation of respiratory dust associated with the Hunter Valley rail corridor$48,626

Funding body: GH Varley Pty Ltd

Funding body GH Varley Pty Ltd
Project Team Associate Professor Yolanda Surjan, Associate Professor Susan Hua, Associate Professor Thomas Fiedler, Professor Kenneth Williams, Coelho, Gabriella, Ms Gabriella Maria Da Silva Coelho, Coelho, Gabriella
Scheme Post Graduate Scholarship
Role Investigator
Funding Start 2017
Funding Finish 2020
GNo G1701315
Type Of Funding C3100 – Aust For Profit
Category 3100
UON Y

Emlyn and Jennie Thomas Postgraduate Medical Research Scholarship$20,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Mrs Yazmin Brown, Professor Pradeep Tanwar, Associate Professor Susan Hua
Scheme Emlyn and Jennie Thomas Postgraduate Medical Research Scholarship
Role Investigator
Funding Start 2017
Funding Finish 2018
GNo G1701211
Type Of Funding C3300 – Aust Philanthropy
Category 3300
UON Y

A targeted drug delivery system for the uterus: characterisation for clinical translation$20,000

Funding body: John Hunter Charitable Trust Grant

Funding body John Hunter Charitable Trust Grant
Project Team

Dr Jonathan Paul, Dr Susan Hua, Dr Bronwyn Andrew

Scheme John Hunter Charitable Trust Grant
Role Investigator
Funding Start 2017
Funding Finish 2018
GNo
Type Of Funding External
Category EXTE
UON N

UON 2017 Researcher Equipment Grant $4,971

Funding body: University of Newcastle

Funding body University of Newcastle
Project Team Associate Professor Susan Hua
Scheme Researcher Equipment Grants
Role Lead
Funding Start 2017
Funding Finish 2017
GNo G1701143
Type Of Funding Internal
Category INTE
UON Y

20163 grants / $578,596

Achieving Targeted Delivery of Drugs to Uterine Muscle in Women for the Prevention of Preterm Labour$483,596

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Laureate Professor Roger Smith, Associate Professor Susan Hua, Professor Sarah Robertson, Associate Professor Kristina Adams Waldorf, Professor Rodney Ho
Scheme Development Grants
Role Investigator
Funding Start 2016
Funding Finish 2018
GNo G1500744
Type Of Funding C1100 - Aust Competitive - NHMRC
Category 1100
UON Y

Brawn Fellowship$75,000

Funding body: Gladys M Brawn Memorial Fellowship

Funding body Gladys M Brawn Memorial Fellowship
Scheme Gladys M Brawn Career Development Fellowship
Role Lead
Funding Start 2016
Funding Finish 2018
GNo
Type Of Funding Internal
Category INTE
UON N

Utilising nanotechnology to target eosinophilic GI disease (EGID)$20,000

Funding body: ausEE Inc.

Funding body ausEE Inc.
Project Team Associate Professor Susan Hua, Laureate Professor Nick Talley, Professor Marjorie Walker
Scheme Research Grant
Role Lead
Funding Start 2016
Funding Finish 2016
GNo G1600470
Type Of Funding C3200 – Aust Not-for Profit
Category 3200
UON Y

20155 grants / $197,625

A Safer Way of Treating Premature Labor and Post- Partum Haemorrhage$66,000

Funding body: Global Alliance to Prevent Prematurity and Stillbirth (GAPPS)

Funding body Global Alliance to Prevent Prematurity and Stillbirth (GAPPS)
Project Team

Roger Smith, Susan Hua and Jonathan Paul

Scheme GAPPS
Role Investigator
Funding Start 2015
Funding Finish 2016
GNo
Type Of Funding International - Competitive
Category 3IFA
UON N

A safer way of treating premature labour and post-partum hemorrhage$65,625

Funding body: Seattle Children's Hospital Research Foundation

Funding body Seattle Children's Hospital Research Foundation
Project Team Laureate Professor Roger Smith, Associate Professor Susan Hua, Doctor Jonathan Paul
Scheme Research Grant
Role Investigator
Funding Start 2015
Funding Finish 2015
GNo G1501339
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

Achieving Targeted Delivery of Drugs to Uterine Muscle in Women for the Prevention of Preterm Labour$48,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Jonathan Paul, Associate Professor Susan Hua, Laureate Professor Roger Smith
Scheme Project Grant
Role Investigator
Funding Start 2015
Funding Finish 2016
GNo G1401504
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

PULSE Early-Career Researcher Award$10,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Associate Professor Susan Hua
Scheme PULSE Early Career Researcher of the Year Award
Role Lead
Funding Start 2015
Funding Finish 2015
GNo G1501377
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

Utilising nanotechnology to target eosinophil driven disease$8,000

Funding body: Faculty of Health, University of Newcastle

Funding body Faculty of Health, University of Newcastle
Project Team

Doctor Susan Hua

Scheme Strategic Research Pilot Grant
Role Lead
Funding Start 2015
Funding Finish 2015
GNo
Type Of Funding Internal
Category INTE
UON N

20142 grants / $73,674

JuLI Stage $71,674

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Professor Pradeep Tanwar, Professor Eileen McLaughlin, Emeritus Professor Robin Callister, Professor Xu Dong Zhang, Professor Murray Cairns, Professor Brett Nixon, Professor Hubert Hondermarck, Associate Professor Phillip Dickson, Associate Professor Nikki Verrills, Professor Matt Dun, Doctor Jessie Sutherland, Doctor Janani Kumar, Professor Jay Horvat, Associate Professor Susan Hua, Prof LIZ Milward, Associate Professor Estelle Sontag, Professor Dirk Van Helden, Doctor Janet Bristow, Doctor Jean-Marie Sontag
Scheme Equipment Grant
Role Investigator
Funding Start 2014
Funding Finish 2014
GNo G1500860
Type Of Funding Other Public Sector - Commonwealth
Category 2OPC
UON Y

The 4th Annual Symposium of drug Delivery System 2014 (SDDS-2014), Suzhou China, 17 - 20 November 2014$2,000

Funding body: University of Newcastle - Faculty of Health and Medicine

Funding body University of Newcastle - Faculty of Health and Medicine
Project Team Associate Professor Susan Hua
Scheme Travel Grant
Role Lead
Funding Start 2014
Funding Finish 2014
GNo G1400807
Type Of Funding Internal
Category INTE
UON Y

20132 grants / $612,956

Understanding the regulation of hERG potassium channel in the myometrium at the time of labour$577,956

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Laureate Professor Roger Smith, Associate Professor Susan Hua, Professor Nick Europe-Finner
Scheme Project Grant
Role Investigator
Funding Start 2013
Funding Finish 2015
GNo G1200367
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON Y

Leica TP 1020 Automatic Tissue Processor for histology applications$35,000

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Professor Pradeep Tanwar, Professor Eileen McLaughlin, Professor Xu Dong Zhang, Conjoint Professor Robert Callister, Associate Professor Phillip Dickson, Professor Hubert Hondermarck, Doctor Jean-Marie Sontag, Professor Dirk Van Helden, Associate Professor Doug Smith, Associate Professor Phil Jobling, Associate Professor Estelle Sontag, Associate Professor Paul Tooney, Associate Professor Susan Hua, Doctor Janet Bristow, Professor Jay Horvat, Prof LIZ Milward, Professor Adam McCluskey, Professor Brett Nixon, Associate Professor Rebecca Lim, Professor Alan Brichta
Scheme Equipment Grant
Role Investigator
Funding Start 2013
Funding Finish 2013
GNo G1201185
Type Of Funding Other Public Sector - Commonwealth
Category 2OPC
UON Y

20122 grants / $21,500

Peripheral immune-derived analgesia: A new target for the treatment of rheumatoid arthritis$20,000

Funding body: Pharmacy Research Trust of NSW

Funding body Pharmacy Research Trust of NSW
Project Team Associate Professor Susan Hua
Scheme Research Grant
Role Lead
Funding Start 2012
Funding Finish 2013
GNo G1101131
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

The 39th Annual Meeting and Exposition of the Controlled Release Society, Quebec City, Canada, 15 - 18 July 2012$1,500

Funding body: University of Newcastle - Faculty of Health and Medicine

Funding body University of Newcastle - Faculty of Health and Medicine
Project Team Associate Professor Susan Hua
Scheme Travel Grant
Role Lead
Funding Start 2012
Funding Finish 2013
GNo G1200581
Type Of Funding Internal
Category INTE
UON Y

20113 grants / $33,381

Development of novel targeted drug delivery systems specifically to sites of inflammation and its application to peripheral analgesia and inflammation in chronic arthritic pathologies$15,581

Funding body: Rebecca L Cooper Medical Research Foundation Ltd

Funding body Rebecca L Cooper Medical Research Foundation Ltd
Project Team Associate Professor Susan Hua
Scheme Research Grant
Role Lead
Funding Start 2011
Funding Finish 2011
GNo G1000741
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

XP6 Micro Balance$12,800

Funding body: Faculty of Health, University of Newcastle

Funding body Faculty of Health, University of Newcastle
Project Team

Susan Hua

Scheme Equipment GRant
Role Lead
Funding Start 2011
Funding Finish 2011
GNo
Type Of Funding Internal
Category INTE
UON N

Peripheral immune-derived analgesia: A new target for the treatment of rheumatoid arthritis$5,000

Funding body: Faculty of Health, University of Newcastle

Funding body Faculty of Health, University of Newcastle
Project Team

Doctor Susan Hua

Scheme Strategic Research Pilot Grant
Role Lead
Funding Start 2011
Funding Finish 2011
GNo
Type Of Funding Internal
Category INTE
UON N

20104 grants / $96,000

Nanopharmaceutics Research Program Establishment$60,000

Funding body: The University of Newcastle

Funding body The University of Newcastle
Project Team

Doctor Susan Hua

Scheme Establishment Grant
Role Lead
Funding Start 2010
Funding Finish 2010
GNo
Type Of Funding Internal
Category INTE
UON N

Malvern Zetasizer $26,000

Funding body: Faculty of Health, University of Newcastle

Funding body Faculty of Health, University of Newcastle
Project Team

Susan Hua

Scheme Equipment GRant
Role Lead
Funding Start 2010
Funding Finish 2010
GNo
Type Of Funding Internal
Category INTE
UON N

Development of Novel Targeted Drug Delivery Systems to Sites of Inflammation$7,395

Funding body: University of Newcastle

Funding body University of Newcastle
Project Team Associate Professor Susan Hua
Scheme Early Career Researcher Grant
Role Lead
Funding Start 2010
Funding Finish 2011
GNo G1000970
Type Of Funding Internal
Category INTE
UON Y

Development of Novel Targeted Drug Delivery Systems to Sites of Inflammation$2,605

Funding body: University of Newcastle

Funding body University of Newcastle
Project Team Associate Professor Susan Hua
Scheme Early Career Researcher (Equipment) Grant
Role Lead
Funding Start 2010
Funding Finish 2010
GNo G1000683
Type Of Funding Internal
Category INTE
UON Y
Edit

Research Supervision

Number of supervisions

Completed13
Current5

Current Supervision

Commenced Level of Study Research Title Program Supervisor Type
2023 PhD Role Of The Community Pharmacist In The Treatment Of Urinary Tract Infections In Women PhD (Pharmacy), College of Health, Medicine and Wellbeing, The University of Newcastle Co-Supervisor
2023 PhD Improving Drug Delivery Into The Brain PhD (Pharmacy), College of Health, Medicine and Wellbeing, The University of Newcastle Principal Supervisor
2023 PhD Enhancing Consumer Use Of Digital Information Through Community Pharmacy PhD (Pharmacy), College of Health, Medicine and Wellbeing, The University of Newcastle Co-Supervisor
2023 PhD Health Policy Impact On The Development Of Community Pharmacy And Scope Of Practice PhD (Pharmacy), College of Health, Medicine and Wellbeing, The University of Newcastle Co-Supervisor
2022 PhD Development of Improved Treatments for Oesophageal Diseases PhD (Pharmacy), College of Health, Medicine and Wellbeing, The University of Newcastle Principal Supervisor

Past Supervision

Year Level of Study Research Title Program Supervisor Type
2024 PhD The Role of Tumour Microenvironment in Ovarian Cancer PhD (Pharmacy), College of Health, Medicine and Wellbeing, The University of Newcastle Co-Supervisor
2023 PhD Electrostatic Interaction of Dust Particles to Solid Surfaces PhD (Mechanical Engineering), College of Engineering, Science and Environment, The University of Newcastle Co-Supervisor
2023 Honours Improving the Treatment of Sarcoptic Mange in Wombats Pharmacy, School of Biomedical Sciences and Pharmcy, The University of Newcastle Principal Supervisor
2023 PhD The Economic Evaluation of Management on Lung Cancer in China PhD (Pharmacy), College of Health, Medicine and Wellbeing, The University of Newcastle Principal Supervisor
2022 PhD The Potential Contribution of Clinical Pharmacist to Quality Use of Medicines in Geriatric Patients in Vietnam PhD (Pharmacy), College of Health, Medicine and Wellbeing, The University of Newcastle Principal Supervisor
2022 Honours Improving the Delivery of Antiparasitic Drugs for the Treatment of Sarcoptic Mange in Wombats Pharmacy, The University of Newcastle Principal Supervisor
2021 Honours Evaluation of techniques for 3D organ imaging Pharmacy, School of Biomedical Sciences and Pharmcy, The University of Newcastle Principal Supervisor
2019 PhD Promoting Quality Use of Medicine in Chronic Respiratory Diseases in Vietnam: The Role of Pharmacists PhD (Pharmacy), College of Health, Medicine and Wellbeing, The University of Newcastle Co-Supervisor
2018 Honours Techniques for assessing nanomedicine biodistribution Pharmacy, School of Biomedical Sciences and Pharmacy, Faculty of Health and Medicine, University of Newcastle Principal Supervisor
2017 Honours Biological imaging of nanomedicines Pharmacy, School of Biomedical Sciences and Pharmacy, Faculty of Health and Medicine, University of Newcastle Principal Supervisor
2015 Honours Therapeutic targeting in disease Pharmacy, School of Biomedical Sciences and Pharmacy, Faculty of Health and Medicine, University of Newcastle Co-Supervisor
2014 Honours Design and development of novel nanoformulations for gastrointestinal drug delivery Pharmacy, Faculty of Health, University of Newcastle Principal Supervisor
2013 Honours Development and characterisation of an effective topical liposomal system for the localised treatment of acute peripheral inflammatory pain Pharmacy, Faculty of Health, University of Newcastle Principal Supervisor
Edit

News

News • 18 Dec 2019

NHMRC awards $9.3 million to 13 University of Newcastle projects

The University of Newcastle has received more than $9.3 million in funding to support projects aiming to solve some of the world’s most critical health problems and improve the lives of millions of Australians.

News • 23 Oct 2017

State leaders in science and engineering announced

Two outstanding University of Newcastle (UON) researchers have been named recipients of the prestigious 2017 Premier’s Prizes for Science and Engineering, announced today at a reception held at Sydney’s Government House.

News • 22 Nov 2016

Excellence in Innovation awarded

Newcastle Innovation hosted their annual Awards ceremony on Friday 18 November at Merewether Surfhouse.

News • 29 Sep 2016

Triple treat for UON: Young Tall Poppies

Three innovative University Of Newcastle and HMRI researchers will be awarded the prestigious title of Young Tall Poppy in the science awards ceremony at the Museum of Applied Arts and Science on Thursday September 29, 2016.

Dr Jonathan Paul

News • 2 Sep 2016

Nanotech revolution for pregnancy drugs

A revolutionary method of delivering drugs specifically to the uterus, using antibody-coated nanoparticles, has been pioneered by researchers from the University of Newcastle (UON) and Hunter Medical Research Institute.

News • 5 Nov 2015

Public health crusader honoured for excellence

The Hunter's health and medical researchers found 80 reasons to celebrate last night as HMRI announced or acknowledged its community-funded grants and prizes during the 2015 Awards Night.

Associate Professor Susan Hua

Position

Associate Professor
School of Biomedical Sciences and Pharmacy
College of Health, Medicine and Wellbeing

Focus area

Pharmacy and Experimental Pharmacology

Contact Details

Email susan.hua@newcastle.edu.au
Phone (02) 49854063
Fax (02) 49217903

Office

Room MS126
Building Medical Science Building
Location Callaghan
University Drive
Callaghan, NSW 2308
Australia
Edit